Targeting epigenetics in sarcomas through EZH2 inhibition
Abstract Soft-tissue sarcomas represent a heterogeneous group of diseases with distinct genetic and clinical features accounting for up to 1% of cancer in adults and 15% of cancer in children. Epithelioid sarcoma is an extremely rare and aggressive tumor affecting young adults that is characterized...
Main Author: | Antoine Italiano |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://link.springer.com/article/10.1186/s13045-020-00868-4 |
Similar Items
-
EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)
by: Simon Leonhard April-Monn, et al.
Published: (2021-10-01) -
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
by: Satoshi Kawano, et al.
Published: (2016-01-01) -
Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC.
by: Amy E Schade, et al.
Published: (2023-04-01) -
Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC
by: Amy E. Schade, et al.
Published: (2023-04-01) -
Epigenetic regulation mechanism of EZH2 gene in hepatocellular carcinoma
by: ZHAO Yu-shan, JI Meng-die, DONG Yu-cheng, GUO Xin, SONG Bo-yuan, CHEN Yang
Published: (2022-06-01)